Asthma as a manifestation of post-COVID syndrome

Introduction. One of the most common complications of the novel coronavirus infection (COVID-19) involves respiratory system disorders, particularly bronchial obstruction. Aim. To highlight the importance of vigilance regarding the onset of respiratory diseases, including asthma, in the post-COVID period. Results. This article describes a clinical case of newly diagnosed severe asthma in a 35-year-old patient following COVID-19. A notable feature of the patient’s condition was prolonged eosinophilia. Sensitization to inhalant allergens was ruled out by a negative Phadiatop ImmunoCAP screening test. Despite receiving a fixed triple combination of an inhaled corticosteroid, a long-acting β 2 agonist, and a long-acting anticholinergic agent, the patient’s disease remained uncontrolled with persistent airway obstruction. A genetically engineered biological therapy was subsequently prescribed, resulting in a marked clinical improvement. Conclusion. This clinical case illustrates a manifestation of post-COVID syndrome—new-onset asthma. Timely diagnosis enables the prompt selection of appropriate therapy, improving the patient’s quality of life and facilitating a return to normal daily activities.